US Stock MarketDetailed Quotes
ATHE Alterity Therapeutics
- 1.7801
- -0.0189-1.05%
Trading Jul 22 10:07 ET
15.76MMarket Cap-887P/E (TTM)
1.8600High1.7801Low15.34KVolume1.8600Open1.7990Pre Close27.88KTurnover0.19%Turnover RatioLossP/E (Static)8.86MShares5.410052wk High1.03P/B14.32MFloat Cap1.550052wk Low--Dividend TTM8.04MShs Float51.5000Historical High--Div YieldTTM4.44%Amplitude1.5500Historical Low1.8170Avg Price1Lot Size
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg
Alterity Therapeutics Stock Forum
Alterity Therapeutics Announced Positive Interim Data From The ATH434-202 Open-label Phase 2 Clinical Trial In Patients With Multiple System Atrophy
Alterity Therapeutics Reports Positive Interim Data from ATH434-202 Phase 2 Clinical Trial in Multiple System Atrophy
Alterity Therapeutics (NASDAQ: ATHE) has reported positive interim data from its ATH434-202 Phase 2 clinical trial for multiple system atrophy (MSA). Key findings include:
▪️43% of participants showed improvement in daily living activities
29% had stable or improved neurological symptoms
▪️Objective biomarkers demonstrated improvement consist...
4 MINUTES AGO, 7:21 PM EDT
VIA GLOBENEWSWIRE
- New bioMUSE Data Informs ATH434-202 Study Endpoints -
- Webcast to Include Key Opinion Leader, Daniel Claassen, M.D., M.S., Vanderbilt University -
Benzinga· 2 mins ago
Alterity Therapeutics ((ASX: ATH, NASDAQ:ATHE) ("Alterity" or "the Company"), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced that an independent Data Monitoring Committee (DMC) has completed its third review of trial data and recommended t...
NEWS
Alterity Therapeutics Phase 2 Data Monitoring Committee Recommends Continuing Clinical Trial As Planned After Third Review
No comment yet